Ranbaxy CEO Malvinder Singh alleged on Friday that some big pharma players are not keen that the Daiichi deal goes through, referring to the US drug authority's charges of the company selling unsafe drugs in the country. Speaking exclusively to NDTV, he said that the US probe on generic companies is part of a larger battle against the company.